Navigation Links
AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds
Date:8/14/2008

eading pharmaceutical companies with healthcare sales of US $29.55 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infection product sales. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index.

National Cancer Centre Singapore

The National Cancer Centre Singapore (NCCS) is the premier cancer research and treatment facility in Singapore and in the region. It was established in 1997 and sees about 68 per cent of the public sector medical oncology cases and 74 per cent of radiation oncology cases. NCCS not only houses the most number of oncologists in Singapore but is also equipped with the largest number of equipment to provide the latest radiation oncology care in Singapore.

National University Hospital

The National University Hospital (NUH) is a specialist hospital that provides advanced, leading-edge medical care and services. Equipped with state-of-the-art facilities as well as dedicated and well-trained staff, NUH is a major referral centre that delivers tertiary care for a wide range of medical specialties including Cardiology, Gastroenterology & Hepatology, Obstetrics & Gynaecology, Oncology, Ophthalmology, Paediatrics and Orthopaedic Surgery. Backed by substantive expertise and experience, the NUH has been chosen by the Ministry of Health to develop two new national specialist centres to meet the growing need for heart and cancer treatments.

NUH, together with the National University of Singapore's Yong Loo Lin School of Medicine and Faculty of Dentistry, are under the common governance of the National University Health System (NUHS). Formed in January 2008, NUHS provides a unified platform for these three entities to create greater synergies to achieve its tripartite mission of excellence in clinical care, translational clinical research and education. With combined capabilities and facilities (from the teaching hospital and m
'/>"/>

SOURCE AstraZeneca
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. AstraZeneca Submits an sNDA for SYMBICORT(R) for the Treatment of Asthma in Children as Young as Age Six
2. Phase III Study of Abbotts Investigational TriLipix(TM) in Combination With AstraZenecas CRESTOR(R) Meets Primary Endpoints on Key Lipids
3. AstraZeneca Submits sNDA for NEXIUM(R) I.V. for Peptic Ulcer Bleed Indication
4. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
5. AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines
6. Volcano Announces Participation in SATURN Clinical Trial Sponsored by AstraZeneca
7. AstraZeneca Submits an sNDA for SYMBICORT(R) for COPD Indication
8. AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression
9. AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer
10. New Analysis of METEOR Study Demonstrate Effects of AstraZenecas CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease
11. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)... BETHESDA, Md., Dec. 4 Drs. Neal Shore and ... recurrence from the additional analysis of secondary end points ... study of FIRMAGON® (monthly degarelix for injection) or monthly ... of treatment. Prostate cancer patients who received FIRMAGON ...
(Date:12/3/2009)... 3 Guidepoint Global, LLC , a leading primary ... Tracker, a monthly longitudinal data release that monitors and projects ... ,, The Sleep Apnea Tracker captures actual patient usage ... United States from 15 different equipment providers going back to ...
(Date:12/3/2009)... (Nasdaq: PCYC ), a biopharmaceutical company focused on ... treatment of immune mediated diseases and cancer, today announced ... on, Tuesday, December 8, 2009 at 11:00am Eastern Time ... clinical data regarding its HDAC Program (PCI-24781) and its ...
Breaking Medicine Technology:Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 2Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 3Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 4Leading Primary Research Firm Guidepoint Global Announces Launch of Sleep Apnea Tracker 2Pharmacyclics to Host Webcast and Conference Call to Discuss Clinical Updates on Its HDAC and BTK Program as Presented at The American Society of Hematology Meeting Dec. 6 & 7 2CareFusion Launches 10 Pound High Performance Critical Care Ventilator in the U S 10347 1CareFusion Launches 10 Pound High Performance Critical Care Ventilator in the U S 10347 2CareFusion Launches 10 Pound High Performance Critical Care Ventilator in the U S 10347 3Many Hospitalized With Swine Flu Had Been Healthy 59397 1Many Hospitalized With Swine Flu Had Been Healthy 59397 2Many Hospitalized With Swine Flu Had Been Healthy 59397 3Scientists urge EPA to adopt systems thinking 10344 1
... Alnylam,Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi ... for Cancer,Research (AACR) 2007 Annual Meeting that ... ALN-VSP01, for the,treatment of liver cancer and ... program. ALN-VSP01 is an RNAi therapeutic that ...
... in Largest-Ever IVF Trial,in US, RANCHO MIRAGE, ... of,four studies evaluating Ferring Pharmaceuticals' ENDOMETRIN(R), a,novel ... phase,support (supplementation to provide support for implantation ... reproductive,technologies (ART) were presented at the 55th ...
Other Medicine Technology:Alnylam Announces Advancement of a New RNAi Therapeutic Development,Program for the Treatment of Liver Cancer 2Alnylam Announces Advancement of a New RNAi Therapeutic Development,Program for the Treatment of Liver Cancer 3Alnylam Announces Advancement of a New RNAi Therapeutic Development,Program for the Treatment of Liver Cancer 4Alnylam Announces Advancement of a New RNAi Therapeutic Development,Program for the Treatment of Liver Cancer 5Ferring Reports on ENDOMETRIN Presentations at Pacific Coast,Reproductive Society Annual Meeting 2Ferring Reports on ENDOMETRIN Presentations at Pacific Coast,Reproductive Society Annual Meeting 3Ferring Reports on ENDOMETRIN Presentations at Pacific Coast,Reproductive Society Annual Meeting 4Ferring Reports on ENDOMETRIN Presentations at Pacific Coast,Reproductive Society Annual Meeting 5
(Date:12/6/2009)... the loss of a key segment of DNA can lead ... show that this kind of genetic alteration can cause obesity. ... The study, led by Dr Sadaf Farooqi from the University ... Sanger Institute, looked at 300 children with severe obesity. , ... of mutation known as copy number variants (CNVs). CNVs are ...
(Date:12/6/2009)... signs of feline DNA in virus , , SUNDAY, Dec. 6 ... AIDS might be found in a tiger that lived thousands ... It appears the virus took on a bit of a ... cat remains in the virus to this day. That tiger, ... evolution of the virus that ultimately led to its infection ...
(Date:12/6/2009)... Dec. 6 Onyx Pharmaceuticals, Inc. (Nasdaq: ... from the pivotal Phase 2b 003-A1 study, known ... well-tolerated in heavily pre-treated relapsed and refractory multiple ... the ASH/ASCO Joint Symposium at the 51st annual ... in New Orleans. Enrollment in this trial is ...
(Date:12/6/2009)... 6 Blood clotting, or coagulation, is ... a blood vessel is injured. Sometimes, however, clots ... obvious injury or do not dissolve naturally, a ... at the 51st Annual Meeting of the American ... using the anticoagulants aspirin and heparin with the ...
(Date:12/6/2009)... and Treatment site www.sleeping-with-a-sleeping-disorder.com is asking ... or natural sleep aids from around the world ... good cause. The submissions will be compiled in ... by YOU, to be sold from the website ... 100% of the proceeds ,from sales of the ...
Breaking Medicine News(10 mins):Health News:Genetic studies reveal new causes of severe obesity in childhood 2Health News:AIDS May Date Back to Ancient Tiger 2Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 2Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 3Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 4Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 5Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 2Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 3Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 4Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 5Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 6Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 7Health News:Donate a Herbal Natural Sleep Aid to the Internet's First "Natural Sleep Aids E-book" Written by People Just Like You 2
... effective in treating wet age related macular degeneration disease which ... macular degeneration is caused due to a chronic degenerative disease ... in the retina which is responsible for proper eye sight. ... of abnormal blood vessel beneath the macula which leads to ...
... Professor Timothy Lohman and colleagues from University of Arizona ... post-menopausal women with calcium supplements and regular exercise makes ... in Bone Mineral Density (BMD) which highly reduces the ... ,Osteoporosis mostly occurs in old age people and ...
... in the Indian State of Orissa are facing a social boycott ... have only their uncle to count on for help. // They ... worked in Mumbai as a laborer for nearly 15 years. When ... Gouranga Naik said. Sourendra who was suffering from AIDS passed away ...
... the environment and are thought to cause cancer in ... bags, stain-free carpets, fast-food wrappers, denture cleaners, windshield washer ... of Toronto had led a team which has investigated ... years. These fluorinated polymers degrade and eventually become a ...
... to be unlucky for Biomedical Tissue Services Ltd a ... cadavers. // The Food and Drug Administration ... donor policies that might pose a threat to transplant ... the patients have been diagnosed with any form of ...
... influenza virus has wrecked havoc on schools with sixty of ... virus and flu. // About 20 schools in Birmingham, Sandwell ... children at these schools were suffering from violent vomiting, diarrhoea ... at the Trinity Primary School, in Hereford. Doug Lowe, the ...
Other Medicine News:Health News:PFCAs Detected in the Artic 2Health News:Chicago :FDA imposes Ban on Biomedical Tissue Services 2
The Model 305 is a hand-held, portable, lightweight oximeter designed for spot checking. It has a NiCad rechargeable battery....
... into comfortable holder, measuring switch is ... is performed., ,Large display of ... surroundings, back light automatically turns on ... compact contour and design provide steady, ...
... The FingerPrint Pulse Oximeter is a ... an integral printer. A light-weight, ... and pulse rate measurements, it ... 4 AA alkaline batteries, and has ...
... The Capnocheck Sleep Capnograph/Oximeter was designed with ... provides reliable measurements of CO 2 ... and can be used for sleep screening as ... generation system utilizes Serial Autocorrelation (SAC) digital pulse ...
Medicine Products: